Welcome to our dedicated page for NewAmsterdam Pharma Co N.V. SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pharma Co N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pharma Co N.V.'s regulatory disclosures and financial reporting.
NewAmsterdam Pharma Co. N.V. director William Lewis reported equity awards from the company. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing a contingent right to one ordinary share, granted for no cash consideration. All of these RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares, with all underlying shares scheduled to vest on January 2, 2027, also conditioned on continued service. Following the RSU grant, Lewis beneficially owned 10,360 ordinary shares directly.
NewAmsterdam Pharma Co. N.V. director John W. Smither reported equity compensation awards. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration. All RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share. These option shares will vest on January 2, 2027, the one-year anniversary of the vesting start date, if he continues in service. After these transactions, he directly owns 10,360 ordinary shares and 15,300 options.
NewAmsterdam Pharma Co. N.V. reported that director Mark C. McKenna received new equity awards. On January 7, 2026, he was granted 3,400 restricted stock units (RSUs), each representing the right to receive one ordinary share. These RSUs will vest in full on the one-year anniversary of the vesting start date, conditioned on his continued service. They were granted for no cash consideration, and following this award he beneficially owns 10,360 ordinary shares directly.
On the same date, McKenna also received an option to acquire 15,300 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036. All shares underlying this option will vest on January 2, 2027, also subject to his continued service, leaving him with 15,300 derivative securities beneficially owned.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported equity awards granted on January 7, 2026. He received 3,400 restricted stock units, each representing a contingent right to one ordinary share, granted for no consideration and scheduled to vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share. All shares underlying this option are scheduled to vest on January 2, 2027, also contingent on continued service. Following these awards, he beneficially owned 10,360 ordinary shares and 15,300 options directly.
NewAmsterdam Pharma Company N.V. furnished an update on its financial position and recent progress. The company reported that unaudited cash, cash equivalents and marketable securities totaled approximately $729 million as of December 31, 2025, providing a view of its liquidity at year-end. This figure was shared in a press release that also highlighted the company’s 2025 achievements and outlined its strategic priorities for 2026.
The press release is included as an exhibit to the report and is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer and director Johannes Jacob Pieter Kastelein reported several equity transactions. On January 5, 2026, he sold 6,000 ordinary shares at a weighted average price of $33.25 per share, in a pre-arranged sale made solely to cover tax withholding tied to vesting restricted stock units, described as non-discretionary.
On January 7, 2026, he acquired 25,500 restricted stock units (RSUs) for no consideration, each RSU representing one ordinary share and vesting in three equal annual installments, leaving him with 98,981 ordinary shares beneficially owned. He also received an option to buy 115,000 ordinary shares at an exercise price of $35.45 per share, expiring January 7, 2036, with 25% vesting on January 2, 2027 and the remainder vesting in equal monthly installments over three years, all subject to continued service.
NewAmsterdam Pharma’s Chief Accounting Officer, Louise Frederika Kooij, reported routine equity compensation activity and a related tax-cover sale. On January 5, 2026, she sold 2,647 ordinary shares at a weighted average price of $33.25 per share in a pre-arranged transaction solely to cover tax withholding from restricted stock unit (RSU) vesting. On January 7, 2026, she acquired 12,000 RSUs, each representing one ordinary share, granted for no consideration, with one-third vesting on each of the first three anniversaries of the vesting start date. She also received an option to buy 53,500 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036, with 25% vesting on January 2, 2027 and the remainder vesting in equal monthly installments over the following three years, all subject to continued service.
NewAmsterdam Pharma Co. N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported several equity transactions in early January 2026. On January 5, 2026, he sold 5,118 ordinary shares at a weighted average price of $33.25 per share to satisfy tax withholding obligations tied to vesting restricted stock units. The filing notes this was a pre-arranged, non-discretionary sell-to-cover transaction.
On January 7, 2026, he acquired 25,500 restricted stock units (RSUs) for no consideration, each representing one ordinary share, with one-third vesting on each of the first three anniversaries of the vesting start date, subject to continued service. He also received an option to buy 115,000 ordinary shares at an exercise price of $35.45 per share, vesting 25% on January 2, 2027 and the remainder in equal monthly installments over the following three years, also contingent on continued service. Following these transactions, he directly beneficially owned 58,382 ordinary shares and 115,000 options.
A holder of NewAmsterdam Pharma Company N.V. has filed a notice to sell ordinary shares under Rule 144. The notice covers 11,582 ordinary shares to be sold through J.P. Morgan Securities LLC, with an aggregate market value of $410,888.61, on the NASDAQ around 01/07/2026. The filing states that there were 113,390,000 shares outstanding. The seller acquired 41,177 ordinary shares from NewAmsterdam Pharma on 01/06/2026 through the vesting of a restricted stock unit (RSU) grant, with the nature of payment described as RSU vesting.
NewAmsterdam Pharma (NAMS) filed its Q3 2025 10‑Q, reporting revenue of $348 thousand and a net loss of $72.0 million. Operating expenses totaled $55.5 million, driven by R&D $31.0 million and SG&A $24.5 million. Other items included a $23.8 million loss from warrant fair value changes and $6.7 million of interest income.
Liquidity remains strong with $756.0 million in cash, cash equivalents and marketable securities as of September 30, 2025. During the nine months, the company recognized $16.1 million related to development cost contributions under its Menarini license and recorded initial supply revenue of $348 thousand after signing a Menarini Supply Agreement on August 12, 2025. On August 18, 2025, the EMA validated MAAs for obicetrapib 10 mg monotherapy and the obicetrapib + ezetimibe FDC. The PREVAIL outcomes trial completed enrollment in April 2024 and could conclude as early as the end of 2026 based on minimum follow‑up and event targets.